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SITC 2018 workshop report: Immuno-Oncology
Biomarkers: State of the Art
Lisa H. Butterfield1, Mary L. Disis2, Bernard A. Fox3, David R. Kaufman4, Samir N. Khleif5, Ena Wang6* and on behalf
of the Society for Immunotherapy of Cancer Immuno-Oncology Biomarkers: State of the Art workshop speakers

Abstract
Identification of biomarkers in cancer immunotherapy that predict therapeutic response and/or limit adverse events
are a critical need in the field. To address recent progress and hurdles around cancer biomarker development and
utilization, the Society for Immunotherapy of Cancer (SITC) convened a workshop, “Immuno-Oncology Biomarkers:
State of the Art,” on May 16–17, 2018. Topics discussed included challenges in handling biospecimens, identification
and validation of new biomarkers, data sharing, and collaborating across disciplines to advance biomarker
development. Panel discussions followed session presentations to help foster participant conversation and discuss
future projects and collaborations. The results of the Workshop include the development of new initiatives for the SITC
Biomarkers Committee.
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Introduction
Immunotherapy interventions, like those eliminating the
interaction between the immune checkpoint proteins
programmed death-1 (PD-1) and its ligand (PD-L1),
have triggered responses in many types of cancer. Despite this exciting progress, only 20–30% of patients respond to immunotherapeutic interventions. The field
needs to better understand treatment failure and how
best to modify treatment for individual patients.
One strategy to increase patient response is predicated
on the identification of reliable predictive biomarkers.
Tumor PD-L1 expression may act as a predictive
biomarker for cancer patients being treated with
anti-PD-1/PD-L1 agents. Furthermore, the anti-PD-1
agent pembrolizumab was recently approved by the US
Food and Drug Administration for the treatment of patients with solid tumors positive for the microsatellite instability (MSI-high) and/or DNA mismatch repair
deficient (dMMR) biomarkers. Tumor mutational burden
(TMB) has also become a biomarker of interest, with studies indicating differential predictive capabilities between
TMB and PD-L1 status in patients being treated with
anti-PD-1/PD-L1 agents [1].
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There is an obvious urgent need to uncover more reliable biomarkers for predicting response to immunotherapy and guiding therapeutic decisions. With the advent
of biomarkers into FDA-approved therapies and the further development of novel technologies including mass
cytometry, gene expression profiling and whole exome
sequencing, The Society for Immunotherapy of Cancer
(SITC) hosted a two day program titled Immuno-Oncology Biomarkers: State of the Art on May 16–17, 2018, to
bring together experts in the field of cancer immunotherapy to discuss opportunities, developments, and
challenges in the cancer biomarker field (Table 1). In
this report, we summarize the critical content of workshop presentations, ideas, and opinions from attendees (Table 2) and highlight next steps planned to
facilitate cross-discipline collaboration to further advance cancer biomarker research and utilization.

Main text
Session I: State of the art - ongoing efforts in Cancer
immune therapy
State of the field and collaborative efforts

Helen Chen, MD (National Cancer Institute, Rockville,
Maryland, USA) introduced the workshop by discussing
the importance of biomarkers through deep tumor and
immune profiling in assessing how an agent or
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Table 1 SITC 2018 Biomarkers Workshop Data Sharing Partnerships
Name of Institution

Objective (related to IO/Biomarkers)

Perspective

National Cancer Institute (NCI)

Address knowledge gaps in cancer immunotherapy to optimize
clinical trial design. Developed the CIMAC-CIDC Network from
the Cancer Moonshot Initiative to establish a standing network
of laboratories and data commons for a systematic approach
to biomarker discovery and validation.

Government

Cancer Immune Monitoring and Analysis Centers
(CIMAC) and Cancer Immunologic Data Commons
(CIDC) Network

Provide systematic support for correlative studies in immunotherapy
trials through a standing network of laboratory centers (CIMACs) for
immune profiling and analysis, and a data center (CIDC) for data
repository, integration and analytical pipelines. The goal is to build the
framework for a sustainable immuno-oncology data resource serving the
NCI trial networks and funded programs and eventually the larger
research community.

GovernmentAcademic-Private
Partnership

Foundation for the National Institutes of Health
(FNIH)

Accelerate biomedical research through collaborations between
NIH and leading public and private institutions. (E.g. FNIH manages
the Biomarkers Consortium, a public-private biomedical research
partnership for identification and development of high-impact biomarkers.)

Government

The Partnership for Accelerating Cancer Therapies
(PACT)

Enhance ongoing efforts within the CIMAC-CIDC network to provide
a systematic approach to IO biomarker investigation in clinical trials.

Public-Private
Partnership

Parker Institute for Cancer Immunotherapy (PICI)

Utilize a collaboration-based model with specific considerations for
standardized data and specimen sharing across all platforms.

Public-Private
Partnership

Cancer Immunotherapy Trials Network (CITN)

Pair cutting edge clinical trials with correlative biomarker studies.
Implementation of centralized operations, quality specimen collection
and processing, competent biobanking, protocols and amendment
management, real-time immune monitoring assays, collaborations
with expert laboratories, and standardized data integration.

Academia

Biden Cancer Initiative

Develop and drive progress in cancer research, especially in assay/data
standardization and harmonization - under Vice President Biden and
Dr. Jill Biden’s Moonshot Initiative.

Non-profit

National Institute of Standards and Technology
(NIST)

Apply transparent, open-sourced standards to cancer research and
clinical care.

Public-Private
Partnership

Alliance-NCI irAE Biorepository

Provide an efficient centralized repository for acquisition, organization
and distribution of biospecimens in clinical trials; to improve treatment
of severe irAEs.

Public-Private
Partnership

Bill & Melinda Gates Medical Research Institute
(The Gates Foundation)

Utilize IO biomarker strategies to develop drugs and vaccines for
tuberculosis, malaria and enteric disease.

Non-profit

combination effects tumor cells, T cells, the tumor microenvironment, and cancer immunity and what determines
response or resistance to a given therapy. Dr. Chen
stressed that correlative studies involving biomarkers are
necessary in order to address the knowledge gaps in cancer immunology and immunotherapy and to optimize
clinical trial design. However, challenges include biological
and technical complexity of tumor and immune profiling
and the need to move from single trial to multi-trial analyses, which requires standardization in assays, data processing and analysis including normalization, scoring and
reporting. Thus, the National Cancer Institute (NCI) developed the Cancer Immune Monitoring and Analysis
Centers (CIMAC) and the Cancer Immunologic Data
Commons (CIDC) Network from the Cancer Moonshot
Initiative. The goal of these centers is to establish a
pre-funded, standing network of laboratories and data
commons for a systematic approach to biomarker discovery and validation, with the immediate goal of supporting
the NCI-funded immunotherapy (IT) trials and the

long-term goal of building the framework for a sustainable
immuno-oncology (IO) data resource serving the larger
research community.
William D. Merritt, PhD (National Cancer Institute,
Rockville, Maryland, USA) discussed the goals and structure of the CIMAC-CIDC network. The primary goal of
this network is to support individual trials and maximize
translational potential by utilizing the collective power
of correlative studies across the NCI trials networks and
funded programs. This network of standing laboratories
and database resources functions by coordinating activities for biomarker discovery and validation in order to
develop molecular signatures that define immune response. Within the network there are four CIMACs
(The University of Texas MD Anderson Cancer Center,
Icahn School of Medicine at Mount Sinai, Dana-Farber
Cancer Institute and Stanford University) and one CIDC
(Dana-Farber Cancer Institute). CIMACs utilize multidisciplinary teams to perform assays and data analysis
using biospecimens from NCI-funded IT trials. All
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Table 2 Immune Profiling and Data Sharing Projects Presented at the SITC Workshop
Name of Project

Institution

Approach

Tumor Neoantigen
Selection Alliance (TESLA)

Parker Institute for Cancer
Immunotherapy

Support efforts to develop safe and effective neoantigen vaccines through
effective neo-epitope prediction algorithms and high-quality epitope
validation sets.

MANAFEST

Johns Hopkins Bloomberg-Kimmel An assay that combines whole exome sequencing, T cell receptor sequencing,
Institute for Cancer Immunotherapy and bioinformatics to identify targetable mutation-associated neoantigens.

APOLLO

MD Anderson Cancer Center

Biomarker discovery by analyzing tissue samples collected during pre-treatment,
treatment and progression.

ECOG 1608 Biomarker project

Sidra Medicine Doha and
ECOG-ACRIN

Combination of cellular immune monitoring assays, in vitro stimulation,
protein profiling, genotyping, and transcriptomic analysis of PBMCs to estimate
the proportion and functional orientation of immune cell subtypes.

Immunoscore/Immunoprofiling

Society for Immunotherapy
of Cancer (SITC)

Objectively measure tumor immune infiltrates using digital imaging
technology to demonstrate correlations with patient prognosis. Develop
standards for next generation multiplex assays.

IBEX (Iterative Bleaching Extends
Multi-pleXity)

National Institutes of Health

An iterative staining method detecting more than 40 protein markers to
highlight immune-tumor interactions.

Peptide MHC tetramer staining

Agency for Science,
Technology and Research

To identify antigen-specific T cells while preserving phenotypic profiles, and
without requiring in vitro expansion.

Multiplexed ion beam
imaging (MIBI)

Stanford University

Determine what cell phenotypes are present in a sample, how the discovered
phenotypes are spatially distributed relative to one another, and how
identified phenotypes are related to a disease state.

1000 Immunomes Project (1KIP)

Stanford University

A systems biology approach to the discovery of biomarkers associated with
systemic chronic inflammation.

Neoantigen Fitness Model

Icahn School of Medicine

A mechanistic model representing the process of immune cell neoantigen
recognition to predict tumor response to therapy.

imCORE global network

Genentech

Centralized testing of samples for data quality monitoring and public access
to standardized clinical trial data.

Project GENIE (Genomics Evidence American Association for
Neoplasia Information Exchange) Cancer Research (AACR)

An international cancer registry that links clinical genotypes to patient outcomes.

Oncology Research Information
Exchange Network (ORIEN)

M2Gen

A cancer center alliance based on the common use of the Total Cancer
Care (TCC) protocol to accelerate cancer discovery through collaborative
learning, partnership and data sharing.

Sparkathon Project TimIOs

Society for Immunotherapy
of Cancer (SITC)

Cross-study analysis of patient response to help further the understanding
of tumor heterogeneity in treating patients with immunotherapy.

CIMACs work as a network to collaborate on eligible trials, including early phase I and phase II immunotherapy
trials, and are overseen by the Laboratory Coordinating
Committee (LCC). As CIMACs accumulate biomarker
data, the CIDC provides a data integration platform for
both clinical and laboratory data to serve the network and
the IO community.

Presentation by four individual CIMAC institutions and CIDC
on opportunities and challenges of working in the network

Sacha Gnjatic, PhD (Icahn School of Medicine at Mount
Sinai, New York, NY, USA) provided an overview of the
assay platforms available across the CIMAC network.
Dr. Gnjatic noted the importance of a multidisciplinary
approach, utilizing the input from immunologists, pathologists, geneticists, tumor biologists, bioinformaticists
and statisticians, in an ideal immune monitoring program balancing innovation with standardization, using
analytically validated assays to minimize variability.

Immune response monitoring should occur both at
the tumor site and at the tumor periphery. The tissue response is measured commonly by multiplex immunohistochemistry (IHC) or immunofluorescence, as well as
immunogenomic approaches including whole exome sequencing (WES)/RNAseq, TCR sequencing, Nanostring/
RT-PCR, and single cell sequencing. Immunopathology
expertise is critical to discern immune cell type and
abundance within the tumor microenvironment, while
immunogenomics provide detailed characterization of
both immune and tumor cells, including tumor mutational burden (TMB) to predict potentially targetable
epitopes. Peripheral immune responses are measured for
cellular composition and function by mass cytometry
from blood, or for soluble analytes or antibody profiling
from serum, as well as for microbiome composition
from stool. Blood and tumor tissues are collected at
multiple time points throughout immunotherapies and
analyzed in a multiscale manner from organ imaging, to
tissue mapping, to cellular mapping, down to molecular
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mapping. The overall data is then compiled and shared
via the CIDC. The ultimate goal of the CIMAC laboratories is to define novel predictive biomarkers of cancer
immunotherapies, by relying on harmonized technologies and protocols. To accomplish this, CIMACs are
working to integrate datasets to define profiles across
specific cancer types or interventions.

Clinical trial working groups within CIMAC-CIDC network

Kara Davis, D.O. (Stanford University, Stanford, California,
USA) discussed how CIMACs can support IO clinical trials.
Biomarker discovery during IO trials is critical to better
understand patient therapeutic response. Dr. Davis referenced the phase I/II COG study, ADVL1412, assessing
safety and efficacy of nivolumab as single-agent or in
combination with ipilumumab in pediatric patients with
solid tumors [2]. Challenges faced for optimal biomarker
integration in this trial included cost, tissue availability,
understanding optimal time points for tissue collection,
competing interests (industry sponsor interests, regulation,
investigator goals, patients’ needs), and logistics (collecting/
shipping high quality samples for biobanking).
As such, the CIMAC/CIDC network is establishing a
clinical trials working group to improve and standardize
cutting-edge, correlative biological studies to be integrated
into clinical trials. This working group will serve as a liaison between trial investigators and CIMACs to optimize
trial design and utilization of CIMAC resources.

Challenges facing CIMACs in patient sample acquisition

Ignacio Wistuba, MD (The University of Texas M.D.
Anderson Cancer Center, Houston, TX, USA) discussed
challenges faced by CIMACs concerning processing and
handling of patient samples and biobanking. One challenge is that tissue samples are inconsistently collected
from patients enrolled in clinical trials. The importance
and necessity to obtain fresh research samples for mechanistic studies and biomarker discovery are well appreciated but not universally implemented in clinical studies.
Due to diverse sample collection methodologies, sample
handling procedures, storage and shipping conditions, collected samples are not always viable or suitable for downstream immune, cellular and molecular assays. Another
challenge is analysis of resected tumor tissue in the neoadjuvant setting. No consensus currently exists on when to
collect tumor tissue and how to establish pathological response. One solution to these challenges is to incorporate
pathologists in the design of the clinical trials and in sample collection, quality assessment, and tissue-based analyses. Overall, it is clear that integrated logistics in clinical
research and sample processing are urgently needed in the
immuno-oncology field.
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Database and informatics issues experienced by CIMACs
and the CIDC

James Lindsay, PhD (Dana-Farber Cancer Institute, Boston, MA, USA) discussed the workflow related to data
analyses conducted throughout the cancer immune monitoring and analysis centers (CIMAC) and the cancer immunologic data commons (CIDC) network. Samples from
eligible clinical trial cohorts will be sent to a CIMAC for
molecular analyses where data is standardized and
uploaded into a cloud based, central data repository. The
CIDC is implementing standardized bioinformatics workflows and supporting integrative biomarker analyses by leveraging the cBioPortal for Cancer Genomics. The CIDC
is piloting its platform in conjunction with a small number
of trials selected by the network.
PACT: A public-private partnership to aid standardization of
immune therapy biomarkers

Stacey Adam, PhD (Foundation for the National Institutes of Health (FNIH), Bethesda, MD, USA) presented
on The Partnership for Accelerating Cancer Therapies
(PACT). PACT is working to enhance ongoing efforts
within the CIMAC-CIDC network by leveraging a 5-year,
$220 million precompetitive public-private research
collaboration - managed by the FNIH - for the
standardization of biomarker and related clinical data to
support the selection and testing of promising therapeutic
combinations. PACT was formed under the Cancer
Moonshot and is made up of the NIH/NCI, FDA and 12
global industry partners. PACT aims to provide a systematic approach to immune and related oncology biomarker
investigation in clinical trials by supporting development
of standardized biomarkers and assays to advance
biomedical research and training collaborations among
government, universities, industry and no-for-profit organizations. The PACT Trial Selection Working Group will
select eligible trials in a flexible manner, allowing for multiple IO trial types to be considered for funding.
Neoantigen selection and the TESLA program

Fred Ramsdell, PhD (Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA) described the Tumor
Neoantigen Selection Alliance (TESLA). TESLA was created by the Parker Institute for Cancer Immunotherapy
and the Cancer Research Institute (CRI) in the fall of
2016. A bioinformatics collaboration, TESLA is comprised
of a global alliance which includes scientists from over 35
of the world’s leading neoantigen research groups in academia, industry and nonprofit. The goal of this consortium is to support efforts to develop safe and effective
neoantigen vaccines by delineating the key parameters necessary for effective neo-epitope prediction algorithms
and generating high-quality epitope validation sets. The
necessity of TESLA is exemplified in the fact that there
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are currently 675 active cancer vaccines, another 372 in
clinical development, and yet nothing has proven particularly effective in large scale trials.
The MANAFEST assay for monitoring anti-tumor immunity

Kellie N. Smith, PhD (Johns Hopkins Bloomberg-Kimmel
Institute for Cancer Immunotherapy, Baltimore, MD,
USA) presented on The Mutation-Associated Neoantigen
Functional Expansion of Specific T Cells (MANAFEST)
Assay – a technology that combines whole exome sequencing, T cell receptor (TCR) sequencing, peptide-stimulated
cultures and bioinformatics to identify targetable
mutation-associated neoantigens (MANAs) found in a
tumor. Ultimately designed to detect a patient’s immune
response to their own tumor, MANAFEST explicitly measures antigen-specific TCR clonotypic amplifications following patient T cell in vitro stimulation with identified
peptide neoantigens [3]. MANAFEST can be used to detect patient response to checkpoint blockade and may be
particularly useful in patients with tumors that have low
mutational burden. This assay overcomes common
problems with the comparable ELISpot assay that may
underestimate the anti-tumor immune response. Translationally, utilization of this assay could potentially lead to
correlation of antigen-specific T cell dynamics with clinical
parameters such as radiographic response, as well as
potentially identifying and measuring dynamics of
antigen-specific clones throughout treatment or disease
progression [3].
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Davide Bedognetti, MD, PhD (Sidra Medicine Doha,
Qatar) concluded the session with preliminary data on
the ECOG 1608 Biomarker project (a collaboration between Sidra, the University of Pittsburgh (Dr. Butterfield
Lab) and ECOG-ACRIN)). This trial (P.I. Stephen Hodi)
tested ipilimumab +/− GM-CSF in melanoma [5]. The
biomarker discovery under this project combines cellular
immune monitoring assays (flow cytometry), in vitro
stimulation (antigen-specific cytokine production), protein profiling (Luminex), genotyping (Illumina MEGAEX
Array), and transcriptomic analysis (Illumina RNA-seq)
of peripheral blood mononuclear cells (PBMC). Thus, by
using deconvolution approaches to estimate the proportion and functional orientation of immune cell subtypes,
combined with a modular framework for subsequent
analysis of any PBMC dataset, [6] shared and treatmentspecific transcriptomic perturbations were detected and
correlated with outcome.
Session I panel discussion outcome

The panel discussed issues of standardization of assays
through the CIMAC network and the need for assay development to keep pace with research in the field, the
need of implement data sharing to facilitate integrative
analysis, the advantages of imaging whole slides versus regions of interest, variation between analytical platforms,
inadequate and non-standardized testing of tissue samples
by pathologists outside of academic hospitals, complexities faced in deep learning models, and biomarkers for
tumor reactivity compared to immune toxicity.

Comprehensive biomarker discovery in immunotherapy
clinical trials: A longitudinal approach

Session II: Identification, analysis and validation of biomarkers
Immunoscore task force: A SITC-led global study

Dr. Wistuba concluded Session I by highlighting MD
Anderson Cancer Center’s Moonshot Initiative program
APOLLO (Adaptive Patient-Oriented Longitudinal
Learning and Optimization), which is working to collect
and process tissue, blood, and other fluids for clinical
trials, including immunotherapy-related trials. As a
cross-disciplinary collaboration between MD Anderson’s
analytical labs, bioinformatics systems, clinical teams and
research activities, APOLLO aims to discover biomarkers
by analyzing tissue samples collected pre-treatment, during treatment and throughout progression. For each participating patient, five core biopsies from solid tumor or
bone marrow aspirates from blood cancers will be analyzed at each time point. High quality specimens and longitudinal approach are the key aspects of this program. A
pilot APOLLO melanoma trial involving tumor tissue analyses of 54 patients being treated with anti-CTLA-4 blockade validated this strategy [4]. In the future, it is intended
that researchers can use data generated from the
APOLLO program to identify biomarkers associated with
immune responsiveness and toxicity.

Bernard Fox, PhD (Earle A. Chiles Research Institute,
Robert W. Franz Cancer Center, Portland, Oregon, USA)
introduced the SITC-led Immunoscore Task Force to attendees. The Immunoscore Validation Project is a global
collaboration, including over 14 countries, with the purpose of introducing immune parameters into tumor classification systems. The immunoscore itself is an objective
measurement of tumor immune infiltrates using digital
imaging technology [7]. Using standardized procedures,
the densities of CD3+ and cytotoxic CD8+ effector T cells
in both the tumor and invasive margin of each patient’s
cancer were processed for immunohistochemistry. Tumor
infiltrating T cell counts were then quantified and compared by digital pathology. An Immunoscore for each patient was derived from the mean of four percentiles based
on cell densities [8]. Positive correlations between tumor
immune infiltrates and prognosis of patients with melanoma [9], head and neck cancer [10], breast cancer [11],
ovarian cancer [12], and colorectal cancer [13] had been
previously reported, but never validated. Thus, SITC provided logistical and infrastructure support to analyze the
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Immunoscore of colon cancer samples collected from patients worldwide. Analyses revealed that the colon cancer
patients with a low Immunoscore experienced faster progression than those with a high Immunoscore. Furthermore, multivariate analyses showed that Immunoscore
was the most significant prognostic biomarker for time to
recurrence (TTR), disease free survival (DFS) and overall
survival (OS). Interestingly, the prognostic outcome based
on a patient’s Immunoscore was independent of the patient’s MSI status. As such, Immunoscore may serve as
the basis for a standardized immune-based assay for the
classification of cancer allowing for stratification of patients enrolled in clinical trials.
Multi-parametric biomarkers I: Seeing is believing – Dissecting
local immune-tumor interactions with advanced imaging
techniques

Dr. Chen Zhao (National Institutes of Health, Bethesda,
MD, USA) presented the recent achievements in advanced
imaging techniques at Dr. Ronald N. Germain’s lab and
how to use these tools to dissect the local immune-tumor
interactions. They have successfully applied histo-cytometry, an innovative and powerful imaging analysis tool developed at Dr. Germain’s lab earlier, to examine the cell
signaling status and function along with phenotype and
spatial information in the tumor microenvironment of
genetically engineered mouse models and patient samples
[14]. To achieve higher complexity, they developed IBEX
(Iterative Bleaching Extends Multi-pleXity), which is an iterative staining method detecting more than 40 protein
markers. Besides that, they are moving forward by combining iterative staining with iterative RNA FISH using
Ce3D (clearing-enhanced 3D microscopy) to develop
highly multiplex 3D datasets. This will help researchers to
understand the complex tumor microenvironment and illuminate immune-tumor interactions.
Multi-parametric biomarkers II: High-dimensional profiling
of cancer-specific vs. bystander tumor infiltrating T cells

Evan Newell, PhD (Fred Hutchinson Cancer Research
Center, Seattle, WA, USA) presented on the role of T
cells in cancer progression. There is a need to profile T
cell phenotypes and antigen specificity to elucidate relevant populations in eliciting immune responses, ultimately assisting in the development of methods to be used
in personalized medicine. High-dimensional T cell
phenotypic profiling reveals a wide range of possible T
cell phenotypes, especially within tumors. By profiling
antigen-specific T cells, researchers can better understand what these profiles mean [15]. For this purpose,
Newell’s group is using peptide MHC tetramer staining
to identify antigen-specific T cells. In conjunction with
mass cytometry, MHC tetramer staining provides a
workflow for T cells to be probed with high levels of
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detail. Such methods allows for analysis of numerous
candidate antigens while preserving phenotypic profiles
and without requiring in vitro expansion. Specifically,
this protocol simultaneously evaluates surface marker
expression, functional capacity and antigen-specificity
[16]. To allow for enhanced antigen-specificity and assessment of hundreds of different antigens in a single
sample, analysis of this process is executed concurrently
with a highly multiplexed method based on combinatorial coding of peptide-MHC tetramers followed by computational data analysis approaches to verify specificity
of staining and determine the extent of cell diversity
[17]. Long-term goals for development and application
of this high-dimensional antigen-specific T cell profiling
technology include finding novel therapeutic targets, discovery of more accurate biomarkers of clinical outcomes
and prediction of immune response to IO therapies [18].
Multispectral imaging: Higher dimensionality imaging approach

Michael Angelo, MD, PhD (Stanford University,
Stanford, CA, USA) presented on the multiplexed ion
beam imaging (MIBI) working principles and how his
team is using the MIBI workflow to explore the role of infiltrating immune cells in triple negative breast cancer
[19]. MIBI is beneficial to researchers as it allows for staining of tissue samples with all mass labeled antibodies at
once instead of using the standard cyclical staining
process, as well as allowing for a stationary sample to be
raster scanned with a particle beam in place of scanning
the sample using lasers on a moving stage. Additionally,
MIBI permits scanning at low resolution to scan the entire
section with all antibody markers, identification of regions
of interest (ROI) and the ability to rescan ROIs at higher
resolutions. This technology is distinct from laser ablation
inductively coupled plasma mass spectrometry
(LA-ICPMS) used by CyTOF instrumentation. MIBI permits quantitative, multiplexed imaging of up to 100-metal
isotope reporters directly in tissue at resolutions down to
200 nm, comparable to brightfield microscopy. Relative to
imaging mass cytometers, MIBI offers an order of
magnitude higher sample throughput and sensitivity while
achieving up to five-fold higher imaging resolution. Such
technological advancements have the potential to improve
understanding of tissue composition through high-dimensional, quantitative analyses in situ [20, 21]. The goal of
MIBI is to determine what cell phenotypes are present,
how the discovered phenotypes are spatially distributed
relative to one another, and how identified phenotypes are
related to a disease state. Furthermore, for analysis of captured images, cells are segmented into single cell networks, clustered into groups, and then analyzed to
compare composition across patient samples. Ultimately,
the goal is to determine which cell types co-localize in a
frequent and meaningful manner such that the
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compartmentalized phenotype correlates significantly with
pathogenesis or clinical endpoints.
Machine learning I

David Furman, PhD (Stanford University, Stanford, CA,
USA) presented the topic of Machine Learning as it is applied to multiscale immune monitoring in systemic chronic
inflammation (SCI) and cancer. It is well established that
chronic inflammation induces epigenetic modifications in
key regulatory genes, which can lead to the initiation of
cancer. Accumulating evidence have also demonstrated that
chronic inflammation can lead to impaired immune system
function leading to poor protection against pathogens and
tumors, known as immunosenescence. However, there is
no consensus regarding which biological markers define
chronic inflammation and how they work to dampen the
immune response. In order to advance clinical understanding of chronic inflammation, the 1000 Immunomes Project
(1KIP) was started to provide a systems biology approach
to the discovery of biomarkers associated with SCI. One
thousand individuals were recruited at Stanford during the
years 2008–2016. These ambulatory subjects were monitored for blood proteomics, cell frequencies, gene expression, in vitro responses to cell stimulations, HLA deep
genotyping, and their serological responses to the influenza
vaccine (in 600 of the individuals). In addition, clinical data
was recorded to derive ‘immune metrics’ for health and
disease. Deep learning algorithms were used to construct a simplified “inflammatory score” (immScore),
which was used to create the first reference values for
standardizing SCI.
Machine learning II: Predicting tumor evolution from
immune interactions

Marta Luksza, PhD (Icahn School of Medicine at Mount
Sinai, New York, NY, USA) discussed a computational
approach to predict tumor evolution from immune interactions. This approach is based on a mechanistic model
representing the process of neoantigen recognition by
immune cells [22]. Her studies show that immune interactions involving neoantigen fitness (the likelihood of presentation by the major histocompatibility complex) and
subsequent neoantigen quality (the ability of neoantigens
to recognize T cells) can influence a patient’s response to
immune checkpoint inhibitors [22]. As such, Dr. Luksza
demonstrates a mathematical fitness model that can predict how tumors respond to immunotherapy by identifying the relative levels of neoantigen quality and fitness.
The goal of machine learning is to quantify the immunogenicity of neoantigens in an evolutionary model
to predict tumor response to therapy. Dr. Luksza explains
that immune interactions with tumor neoantigens affect a
cell’s fitness such that a cancer cell recognized by T cells
will not replicate as well as one that isn’t. Dr. Luksza
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presented the Neoantigen Fitness Model which was created to score the recognition potential of a peptide (s) by
accounting for both components necessary for immune
recognition: peptide’s presentation by MHC and subsequent recognition by T-cell receptors. Both components
are quantified based on modelling the probability of the
underlying biophysical interactions, namely of binding between a peptide and the MHC, and binding of a presented
peptide and a host’s T-cell receptor.
The goal of using prediction models is to be able to rationalize health care decisions and understand or modify
treatments. However, the high dimensionality of genomic sequences and genetic heterogeneity of tumors
makes response prediction difficult as a single tumor
may have multiple immune interactions due to its multiple neoantigens. This approach, which utilizes both a
mechanistic model and biophysical immune interactions,
employs prior knowledge regarding evolutionary dynamics to reduce the complexity of machine learning.
Session II panel discussion outcome

The Discussion panel recommended the need for reference materials for standardization, the need to move the
Immunoscore towards a reimbursable pathology test,
and the hurdle of tumor heterogeneity and limited biopsy samples.
Session III: Data and specimen sharing
Cancer immunologic data commons (CIDC)

James Lindsay, PhD (Dana-Farber Cancer Institute,
Boston, MA, USA) presented the CIDC’s view on data. The
guiding principles behind the CIDC data sharing network
include: 1. providing data quickly to researchers, 2. forming
a standardized network of software and bioinformatics
tools, and 3. focusing on software innovation unique to the
biomarker space. Additionally, all content needs to meet security requirements and be standardized prior to access as
described by the FAIR (Findable Accessible Interoperable
Reusable) data ethos, emphasizing that data harmonization
is imperative for effective data sharing.
Dating sharing for PACT and FNIH

Stacey Adam, PhD (Foundation for the National Institutes
of Health, Bethesda, MD, USA) spoke on key data sharing
principles used within ongoing FNIH public-private
partnerships (PPP). One discussed ‘key’ for current and future PPPs is flexibility to allow the needs of the partnership dictate the model. This includes considerations such
as the motivating scientific need for involved stakeholders,
sharing models, availability for broad public research use,
inclusivity of appropriate partners, and IP policy
considerations.
The Partnership for Accelerating Cancer Therapies
(PACT) is one of the newer FNIH PPPs. PACT-selected
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trials can be conducted by a number of sources, but a set of
standardized biomarkers will be run by the CIMACs. The
trials receive supplemental funding in exchange for depositing their sponsored biomarker and accompanying
de-identified clinical data to the CIDC for public use. Logistically, CIMACs deposit raw data from their involved trials
into the CIDC, where data is de-identified and analyzed for
publication and IO community use. PACT utilizes a tiered
data access structure, providing data access first to trial investigators and sponsors, next to PACT partners, and then
the public. Despite progress, several challenges remain including building data sharing infrastructure, trial recruitment speed, patient consent, potential international
regulatory approval, standardization to a common clinical
data standard (CDISC), and IP guidelines.
Ongoing advanced correlative assays at the Parker Institute
for Cancer immunotherapy (PICI)

Pier Federico Gherardini, PhD (Parker Institute for Cancer
Immunotherapy, San Francisco, CA, USA) discussed efforts at PICI to deal with challenges from advanced correlative assays, from both a logistical and data analysis
perspective. PICI utilizes a collaboration-based model for
their ongoing projects, with specific considerations for
data and specimen sharing across all platforms. On the logistics side, planning in advance for appropriate sample
collection and aliquoting is fundamental if several assays
are to be run in parallel. Moreover Dr. Gherardini underscored the challenges of standardization, even for
well-established assays. On the data analysis side Dr.
Gherardini highlighted how issues such as missing data,
and small datasets make the application of Machine
Learning challenging. To address these analytical challenges, PICI has assembled a central computational team
that is well versed in biology and works in close collaboration with the investigators. The underlying assumption is
that deeper molecular characterization of the samples will
lead to more opportunities for novel discovery.
Industry perspective

Priti Hegde, PhD (Genentech, San Francisco, CA, USA)
discussed an industrial perspective on data and specimen
sharing. Driven by the belief that high-quality data is
critical in advancing progress against cancer, industry is
an advocate of centralized sample testing and data quality monitoring as well as fostering public access to standardized clinical trial data. There is a need for clear
hypotheses and study design regarding statistical significance in biomarker analyses, viable specimen acquisition
protocols, and assay qualification. To implement centralized testing of samples for data quality monitoring and
public access to standardized clinical trial data, Dr.
Hegde’s institution initiated imCORE, a global research
network of 21 academic centers, where scientists can
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readily share technology, data, and expertise. This is exemplified in a 326 patient Phase II urothelial bladder
cancer clinical trial for atezolizumab, IMvigor210, where
all RNAseq, WES, CD8 IHC, PD-L1, and outcome data
has been made publicly available [23].
Academic perspective

Samir N. Khleif, MD (Georgetown University, Washington D.C.) shared an academic perspective on challenges
and opportunities encountered in data sharing. It has become clear that data sharing enables the exploration of
topics and correlations potentially disregarded by initial
analyses. However, although data sharing is vital to the
development of clinical trials to reduce both time and
cost, academics face many challenges.
Academics often face challenges in accepting the validity
of data from other sources. Ethical considerations also must
be accounted for, including responsible data management,
verification, and ownership. Legal challenges including privacy regulations and data exchange between countries can
also become problematic. Cultural challenges can arise as
well, including the reluctance to share data in academia,
claiming credit, as well as promotion and tenure
procedures. IP ownership and high costs of implementing
data sharing solutions in addition to technical challenges
such as data storage, management, standardization, and
harmonization can also serve as barriers.
Cancer immunotherapy trials network (CITN): Data management
and specimen sharing

Martin Cheever, M.D., and Steven Fling, PhD (Fred
Hutchinson Cancer Research Center, Seattle, WA, USA)
presented on the Cancer Immunotherapy Trials Network
(CITN). Funded by the National Cancer Institute and the
Fred Hutchinson Cancer Research Center, the CITN is
comprised of 30 member sites (29 US-based, 1 Canadian),
and is working to accelerate immunotherapy development
by pairing cutting edge clinical trials with correlative biomarker studies. Thus far, anti-PD1 and anti-PD-L1 immunotherapy dominates the field, making it likely that
many patients will be considered for anti-PD1/PD-L1
therapy alone or in combination. Patients failing these
treatments will become the largest population of cancer
patients. With the many available agents to be potentially
used in combination with checkpoint inhibitors, rapid biomarker analyses are imperative to discern optimal agents
with which to move forward. To address this challenge,
the CITN implemented a comprehensive framework, including centralized operations, quality specimen collection
and processing, competent biobanking, management to
match protocols and amendments, real-time immune
monitoring assays, close collaborations with expert laboratories, and a standardized procedure for data integration.
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This framework can help researchers rapidly initiate trials
and better understand treatment failure.
The CITN has put into place two integrated repositories: BioSpecimens (BSI-II) and Correlative Science Data
(LabKey). BSI is an interface used by CITN to communicate with clinical sites by posting information in real-time
and tracking all specimens. Labkey is a web-based system
for managing data, allowing users to visualize study
organization. Any user with access can view raw and analyzed data within and across studies. Alignment of these
two systems and coordination of data between them is
fundamental in accelerating progress.
AACR project GENIE

Shawn Sweeney, PhD (American Association for Cancer
Research (AACR), Philadelphia, PA, USA) presented on
AACR’s Project GENIE (Genomics Evidence Neoplasia
Information Exchange), an international cancer registry
that links clinical genotypes to patient outcomes with
the goals of driving clinical decision making and translational research. The GENIE registry currently contains
data from over 48,000 sequenced tumors from the eight
founding institutions and has recently completed an expansion to a total of19 participating institutions and
their associated cancer centers. Of the participants, there
are 14 medical centers from the United States, 4 from
Europe and 1 Canadian institution.
Project GENIE collects both genomic and clinical data,
each with distinct analytical pipelines and processes.
Concerning genomic data, Project GENIE analyzes several
biomarkers, including microsatellite instability (MSI),
DNA mismatch repair deficiency (dMMR), tumor mutational burden (TMB), and holds the ability to analyze
other co-occurring mutations. Currently, a pragmatic set
of baseline clinical data are collected on every patient with
more detailed clinical data and outcomes collected on specific cohorts. The consortium is currently in the process
of expanding the data collected as part of the baseline
through a multiyear staged project. In addition to the genomic and clinical data, the BAM files; nucleic acid libraries; stained slides; and in many cases, tissue, are available
and can be used to drive further discovery. One ongoing
project is working to correlate calculated MSI, TMB, and
dMMR results with SOC testing (PCR and IHC) as well as
outcomes to immune checkpoint blockade therapy.
Oncology research information exchange network (ORIEN)

Hongyue Dai, PhD (M2Gen, Tampa, FL, USA) presented
on the Oncology Research Information Exchange Network (ORIEN) - a cancer center alliance of 18 US-based
academic medical centers grounded on the common use
of the Total Cancer Care (TCC) protocol. The mission of
ORIEN is to accelerate cancer discovery through collaborative learning, partnership and data sharing. TCC,
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which was developed at Moffitt Cancer Center, is the largest prospective observational study of its kind in the cancer arena, allowing for patients to be followed throughout
their lifetime to better identify, meet, and ultimately
predict clinical need. ORIEN Avatar – an ORIEN project focuses on cohorts of high-risk patients and those with
unmet medical needs, including clinical trials. The project
collects detailed longitudinal clinical data, and generates
uniform in-depth molecular data, to promote and enable
both the matching of patients to clinical trials as well as
collaborative research among cancer centers and between
cancer centers and industry partners.
Biden Cancer initiative

Catharine Young, PhD (Biden Cancer Initiative, Washington, D.C.) next presented the Biden Cancer Initiative: Ending cancer as we know it. The Biden Cancer Initiative
brings to life Vice President Biden’s and Dr. Jill Biden’s vision of a day when we can effectively diagnose, treat and
care for every patient afflicted by cancer. The Biden
Cancer Initiative recognizes that clinical analyses cannot
be compared across institutions, severely limiting second
opinions, collaboration, and access to medical records,
thus placing a significant need for assay standardization
and harmonization. As such, the Biden Cancer Initiative is
currently working on a pilot study testing an arrangement
where patients, treatment centers and industry can contribute de-identified data for qualified visualization and
analysis. In regard to standardization, the Biden Cancer
Initiative is working with the National Institute of
Standards and Technology (NIST) to convene public and
private sector experts with the mission of bringing
pre-existing, open-source standards to cancer research
and clinical care. The core mission of this initiative is to
create the cancer research and health care system that patients expect and think we already have.
Immune-related adverse events

John M. Kirkwood, MD (University of Pittsburgh and
UPMC Hillman Cancer Center, Pittsburgh, PA, USA) next
presented on inflammatory and autoimmune toxicities associated with immuno-oncology therapies. With the recent
advancements and FDA approvals in immunotherapy, IO
agents will be used in millions of patients with advanced
disease, adding years of subsequent survival. With the most
recent approvals of anti-PD1 agents for the adjuvant setting, even larger populations of patients who do not necessarily have late stage disease, and who are destined for
relapse or progression will be treated. Toxicities experienced due to treatment with immunotherapies, or irAEs,
pose a significant issue regarding future treatments and
combinations for patients who may otherwise experience
significantly improved long-term survival.
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As such, there is a need to establish an efficient centralized repository for acquisition, organization and distribution of well-annotated biospecimens for translational
studies to improve the understanding of molecular pathogenesis and treatment of severe irAEs. This need has been
addressed through the Alliance-NCI irAE Biorepository,
an intergroup consortium which aims to 1. Develop biospecimen and clinical data collections from retrospectively
identified trial patients with irAEs; 2. Develop a mechanism for the prospective collection of data and biospecimens from trial patients with new onset irAEs to be
analyzed using the irAE biorepository protocol; and 3.
Pilot a prospective registry and biobanking trial for patients who develop irAEs receiving standard of care IO
therapies at Washington University and Dana-Farber Cancer Institute. Better understanding of the mechanism (s)
of IO induced autoimmune toxicities may aid in mitigation of these toxicities in the future.
Sparkathon project TimIOs

Yana Najjar, MD (University of Pittsburgh, Pittsburgh, PA,
USA) and Randy Sweis, MD (University of Chicago, Chicago, IL, USA) discussed the TimIOs project, developed
through SITC’s Sparkathon initiative, to conduct a pooled
analysis of durable versus transient responders enrolled in
immunotherapy clinical trials. SITC’s Sparkathon program
brings together early-career scientists of different backgrounds to address current hurdles in the field of IO. The
SITC Sparkathon Class of 2017, which created Team
TimIOS, included 29 emerging leaders from global academic medical centers, US-based government agencies
and one US-based private institution. TimIOs was granted
funding to develop tools for advancing understanding of
tumor heterogeneity and clinical response, and subsequently proposed a unified public-private consortium
where TimIOs would act as an honest broker to facilitate
cross-institution collaboration. TimIOs aims to build a
platform that will help identify fundamental differences
between two patient response cohorts: durable (partial or
complete response longer than 2 years) vs transient
(partial or complete response shorter than 6 months) responders, and elite responders (patients with complete response) vs rapid progressors.
Session III panel discussion outcome

The panel discussed identifying immune health through
the use of standardized CyTOF panels within the
CIMACs, analyzing CMV responses in cancer patients,
examining immune health across diverse diseases, profiling immune competency and irAEs, whether immune
toxicity associated with checkpoint blockade is related to
the administration of the antibodies themselves or T
cells, funding for development of therapeutic antibodies
versus T cell research, how best to combine datasets to
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conduct cross-study analyses, preclinical modeling of adverse events, and the pros and cons of closed versus
open data networks.
Session IV: Collaboration across disciplines
Collaborative and integrated approach to Immuno-oncology
biomarkers at PICI

Theresa LaVallee, PhD (Parker Institute for Cancer
Immunotherapy (PICI), San Francisco, CA, USA) discussed PICI’s efforts to bring a cross-disciplinary approach
to cancer immunotherapy guided by the field’s top scientists. For instance, one venture entails collaborative efforts
to advance personalized cancer treatments through
neoantigen discovery. Here, PICI has convened experts to
identify optimal algorithms for prediction of neoantigens
that will generate an immune response and has completed
initial predictions regarding vaccine development for the
treatment of patients with melanoma and NSCLC.
Increasing the field’s understanding of immune-related
adverse events (irAEs) is also a major PICI goal. Researchers are beginning to understand that irAEs are not
simply toxicities but are rather a pharmacodynamic activity of immune agents. Endocrinopathies, for example,
are an example of a byproduct of an immune response
that is related to the drug’s mechanism. To better understand and prevent irAEs, PICI is currently researching
irAE mechanisms following checkpoint inhibition in
cancer patients to identify at-risk patients early and determine if the irAE is similar to the natural presentation
of the same pathological condition.
Additionally, PICI is invested in understanding the
role of the microbiome in cancer. Emerging data reveal
that a patient’s microbiome composition may correlate
with response to anti-PD-1 therapy. PICI plans to launch
a microbiome-cancer immunotherapy trial for patients
with advanced melanoma in order to facilitate transition
of microbiome analyses into the clinic [24].
Infectious disease and biomarkers I: Gates medical research
institute

David Kaufman, MD, PhD (Bill & Melinda Gates
Medical Research Institute, Cambridge, MA, USA) described progress in global health over the past couple of
decades, including the near-elimination of polio, introduction of the meningitis vaccine into central Africa,
cutting AIDS-related deaths in half, and significant
drops in infant mortality in sub-Saharan Africa.
Many challenges remain in this area, however. To address these challenges, The Gates Foundation has
launched the Bill & Melinda Gates Medical Research Institute—a ‘nonprofit biotech’ to drive the development of
drugs and vaccines for tuberculosis, malaria and enteric
disease. The Gates Medical Research Institute will develop
small molecules, vaccines, biologics and biomarkers across
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pre-clinical and clinical settings with a focus on moving
lead candidates through proof of concept clinical studies.
The Gates Medical Research Institute plans to utilize
many of the cutting-edge translational medicine and biomarker strategies currently being pioneered in the
immuno-oncology field.
Infectious disease and biomarkers II: Viral biomarker discovery
using CyTOF

Holden T. Maecker, PhD (Stanford University Medical
Center, Stanford, CA, USA) discussed analyses of viral infection using CyTOF to elucidate specific T cell subsets
correlating to an immune response against infectious disease. Markers indicating the presence of cytotoxic CD8+
T cells, multifunctional T cells, and central memory or effector memory T cells can all be analyzed using CyTOF,
and without fluorescence spillover problems experienced
in conventional flow cytometry. CyTOF disadvantages,
however, include difficulties in analyzing very rare cell
populations, and increased time for sample acquisition.
Examples of recent efforts utilizing CyTOF include
analyzing CMV-specific T cell profiles in lung transplant patients to predict whether they were at risk for
viremia/rejection post-transplant, as well as predicting
RSV vaccine response in elderly patients.
Biomarkers in autoimmunity

Zoe Quandt, MD (University of California San Francisco,
San Francisco, CA, USA) discussed the use of biomarkers
in combating irAEs due to autoimmune disease. Autoimmunity as a mechanism of pathogenesis is an alteration
to immune function in terms of selection, T cell or B cell
regulation, or an aberrant response to a particular antigen.
Dr. Quandt’s research focuses on immune checkpoint
inhibitor-induced diabetes mellitus (CPI-DM), which
is largely observed in patients being treated with
anti-PD1/PD-L1 therapy. Interestingly, in Dr. Quandt’s
study, CPI-DM patients treated with checkpoint blockade
experienced an autoantibody prevalence (generally
thought to be non-pathogenic in DM) of 40% -- significantly lower than the autoantibody prevalence in conventional Type I Diabetes patients (95%). Further investigation
revealed that patients treated with PD-1/PD-L1 inhibitors
positive for autoantibodies developed earlier onset of
CPI-DM, suggesting that these types of biomarker analyses
may be able to help predict autoimmune-related irAEs [25].
Session IV panel discussion outcome

The panel weighed in on executing the Team TimIOS
project, anticipated complications in acquiring and harmonizing clinical data, adopting new standards in clinical
workflows, prioritizing access to data before perfecting the
system, and deriving benefit from experts across disciplines to overcome current data sharing hurdles.
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Conclusions and next steps
Immunotherapy clinical trials are redefining how scientists
and clinicians approach patient care. With the continued
need for testing of novel agents and combination therapies, SITC’s Immune Biomarkers Committee reconvened to
review and evaluate state of the art technologies, identify
current hurdles, and to form working partnerships within
the immunotherapy biomarkers arena. Throughout the
workshop sessions, two major issues emerged harmonization of data and novel biomarker discovery.
Harmonization and standardization of data generated
from widely used assays and technologies is a major hurdle
for the entire scientific community. From basic scientific
discovery to clinical practice, there is a lack of universal
standards on nomenclature, language, definitions, scoring,
reporting, SOPs and global approvals, and a lack of comprehensive efforts to develop necessary standards. For instance, the lack of standardized diagnostic tests which
measure biomarkers such as PD-L1 demonstrate the far
reaching logistical and technical problems in improving
therapeutic development and patient response - PD-L1 is
currently measured by numerous assays with antibodies expressing various levels of positive expression. For this reason, institutional collaborations such as the described
efforts between the CIMACs and CIDC share the objective
of creating a harmonized, systematic approach to biomarker discovery, utilization and validation. Such networks
share the ultimate goal of advancing correlative biological
studies through the coordination of technological assays
and protocols. Ultimately, harmonization of data will not
only enable further investigation of scientific ideas and correlated discoveries but will lead to an eventual reduction in
time and more efficient therapeutic development.
Furthermore, to overcome complex hurdles and encourage the development of personalized medicine, more sophisticated assays and systematic approaches are needed.
Such cutting-edge technologies may be better equipped to
address scientific and clinical issues, namely identification
of novel biomarkers to better predict patient response to
therapies. Thus, the second focus of discussion centered
on biomarker discovery through emergent and transformative technologies. The workshop recognized many
breakthrough technologies, including, but not limited to
the MANAFEST assay which combines WES and TCR
sequencing for determination of individual immune response, 3D tissue staining and microscopy to better explore the tumor microenvironment, MIBI for multiplex
imaging using up to 100 antibodies, and high dimensional
T cell profiling to identify antigen-specific T cells.
Additionally, machine learning approaches such as the
neoantigen fitness model and deep learning algorithms as
applied to monitoring of biological immune markers in
the 1000 Immunomes Project highlight evolving computational approaches. Such technologies are poised to test
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new hypotheses more rapidly and produce comprehensive
informatics datasets in order to target and validate newly
discovered biomarkers and drive therapeutic development.
Based on the data presented and the interactive discussion panels, several next steps were identified to address
the bi-level discussion which emerged from the workshop.
1) Members of the existing SITC Biomarkers Task Force
will identify SOPs and methodological publications to post
to the SITC website as a resource. 2) Task Force members
will work together to identify technologies and co-authors
for an updated series of Biomarker Technology primers
for JITC. 3) A new multispectral imaging task force will be
created to share best practices in this technology platform
to further its optimal utilization. 4) The images from
SITC’s Immunoscore Validation Task Force will work to
share these images for future analysis. 5) A new
immune-oncology data sharing task force will also be convened by SITC.
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